MX356517B - Polipéptidos de fusión de serpina y métodos de uso de los mismos. - Google Patents

Polipéptidos de fusión de serpina y métodos de uso de los mismos.

Info

Publication number
MX356517B
MX356517B MX2013015323A MX2013015323A MX356517B MX 356517 B MX356517 B MX 356517B MX 2013015323 A MX2013015323 A MX 2013015323A MX 2013015323 A MX2013015323 A MX 2013015323A MX 356517 B MX356517 B MX 356517B
Authority
MX
Mexico
Prior art keywords
polypeptide
derived
methods
molecules
amino acid
Prior art date
Application number
MX2013015323A
Other languages
English (en)
Other versions
MX2013015323A (es
Inventor
Brendan P Eckelman
John C Timmer
Peter L Nguy
Grant B Guenther
Quinn Deveraux
Original Assignee
Inhibrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Llc filed Critical Inhibrx Llc
Publication of MX2013015323A publication Critical patent/MX2013015323A/es
Publication of MX356517B publication Critical patent/MX356517B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Abstract

La presente invención se refiere a una proteína de fusión aislada, caracterizada porque comprende por lo menos un polipéptido de serpina de humano que comprende un polipéptido de alfa-1 antitripsina (AAT) de humano que comprende una secuencia de aminoácidos seleccionada del grupo que consiste de SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID: 32 y SEQ ID NO:33, en donde el polipéptido de AAT está enlazado operablemente a un polipéptido de Fc de inmunoglobulina que comprende la secuencia de aminoácidos de SEQ ID NO: 6.
MX2013015323A 2011-06-28 2012-06-28 Polipéptidos de fusión de serpina y métodos de uso de los mismos. MX356517B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161502055P 2011-06-28 2011-06-28
US201161570394P 2011-12-14 2011-12-14
US201161577204P 2011-12-19 2011-12-19
US201261638168P 2012-04-25 2012-04-25
PCT/US2012/044730 WO2013003641A2 (en) 2011-06-28 2012-06-28 Serpin fusion polypeptides and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2013015323A MX2013015323A (es) 2014-06-23
MX356517B true MX356517B (es) 2018-06-01

Family

ID=47424806

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015323A MX356517B (es) 2011-06-28 2012-06-28 Polipéptidos de fusión de serpina y métodos de uso de los mismos.

Country Status (27)

Country Link
US (7) US8980266B2 (es)
EP (2) EP3569243A1 (es)
JP (4) JP2014523900A (es)
KR (5) KR20220003656A (es)
CN (3) CN103917563A (es)
AU (4) AU2012275287B2 (es)
BR (1) BR112013033799A2 (es)
CA (2) CA3132298A1 (es)
CY (1) CY1122195T1 (es)
DK (1) DK2726092T3 (es)
ES (1) ES2746052T3 (es)
HR (1) HRP20191652T1 (es)
HU (1) HUE046156T2 (es)
IL (2) IL230209B (es)
IN (1) IN2013MN02441A (es)
LT (1) LT2726092T (es)
ME (1) ME03473B (es)
MX (1) MX356517B (es)
NZ (1) NZ744257A (es)
PL (1) PL2726092T3 (es)
PT (1) PT2726092T (es)
RS (1) RS59368B1 (es)
RU (5) RU2727452C1 (es)
SG (2) SG10201601621PA (es)
SI (1) SI2726092T1 (es)
UA (1) UA124083C2 (es)
WO (1) WO2013003641A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102103476B1 (ko) 2011-06-24 2020-04-23 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
US8986688B2 (en) * 2011-06-28 2015-03-24 Inhibrx, Llc WAP domain fusion polypeptides and methods of use thereof
WO2013003641A2 (en) * 2011-06-28 2013-01-03 Inhibrx Llc Serpin fusion polypeptides and methods of use thereof
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
EP2802653A4 (en) 2012-01-10 2015-09-02 Univ Colorado Regents ALPHA-1 ANTITRYPSIN FUSION MOLECULE COMPOSITIONS, METHODS AND USES THEREOF
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
KR101509020B1 (ko) * 2013-05-22 2015-04-14 (주)입디 알파 1 안티트립신 융합 분자에 대한 조성물, 방법 및 용도
US20170190762A1 (en) 2014-06-11 2017-07-06 Beth Israel Deaconess Medical Center, Inc. Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases
CA3161989A1 (en) * 2014-07-23 2016-01-28 Inova Diagnostics, Inc. Compositions and methods for the diagnosis of rheumatoid arthritis
SG11201703390SA (en) * 2014-10-27 2017-05-30 Inhibrx Lp Serpin fusion polypeptides and methods of use thereof
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US11422719B2 (en) * 2016-09-15 2022-08-23 Pure Storage, Inc. Distributed file deletion and truncation
WO2018183705A1 (en) * 2017-03-29 2018-10-04 Cornell University Oxidation-resistant aat gene therapy
US11426368B2 (en) 2017-07-27 2022-08-30 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use
FI3716998T3 (fi) 2017-12-01 2024-04-16 Csl Behring Llc A1at akuutin käänteishyljintätaudin puhkeamisriskin vähentämiseksi hematopoieettisten solujen siirron jälkeen
WO2020092448A1 (en) 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
CN114502529A (zh) * 2019-08-01 2022-05-13 赛尔普拉斯科技有限公司 抗氧化的丝氨酸蛋白酶抑制剂
CN110964094B (zh) * 2019-12-20 2021-11-02 华中科技大学 人源白细胞蛋白酶抑制因子及其重组制备与应用
CN112341538A (zh) * 2020-10-27 2021-02-09 苏州复融生物技术有限公司 一种Fc单体多肽及其应用
WO2022162533A1 (en) * 2021-01-26 2022-08-04 National Research Council Of Canada Ace2-receptor ectodomain fusion molecules and uses thereof
GB202102258D0 (en) 2021-02-17 2021-03-31 Arecor Ltd Novel composition
WO2023122120A1 (en) * 2021-12-22 2023-06-29 The Regents Of The University Of California Compositionsand methods for wound healing
WO2023225513A1 (en) 2022-05-16 2023-11-23 Inhibrx, Inc. Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
WO1992019759A1 (en) 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5734014A (en) 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1161532A1 (en) * 1999-03-01 2001-12-12 Human Genome Sciences, Inc. Human serpin proteins
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
ATE330967T1 (de) 1999-07-02 2006-07-15 Genentech Inc An her2 bindende peptidverbindungen
AU2050501A (en) * 1999-12-01 2001-06-12 Human Genome Sciences, Inc. Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies
CA2747325A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
FR2814957B1 (fr) 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
CN1561220A (zh) * 2000-11-08 2005-01-05 普罗米蒂克生物科学公司 炎症的治疗方法
PL209550B1 (pl) 2000-12-07 2011-09-30 Lilly Co Eli Heterogenne białko fuzyjne, kompozycja farmaceutyczna do leczenia pacjentów z cukrzycą insulinoniezależną i kompozycja do leczenia pacjentów z otyłością
EP2341060B1 (en) * 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
AU4166102A (en) * 2000-12-18 2002-07-01 Arriva Pharmaceuticals Inc Multifunctional protease inhibitors and their use in treatment of disease
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
WO2002076489A1 (en) * 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
US7737260B2 (en) * 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1415664A1 (en) * 2002-10-30 2004-05-06 Switch Biotech Aktiengesellschaft Use of alpha 1-antichymotrypsin in combination with alpha-1-antitrypsin for treating/preventing diabetes associated or poorly healing arterial wounds
US7427595B1 (en) 2002-12-12 2008-09-23 Cornell Research Foundation, Inc. Use of proepithelin to promote wound repair and reduce inflammation
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
DK1641483T3 (da) 2003-06-12 2008-06-02 Lilly Co Eli Fusionsproteiner
EP3192872A1 (en) * 2003-08-26 2017-07-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
AU2005221151A1 (en) * 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
CA2561533C (en) 2004-04-13 2015-06-16 Yvo Graus Anti-p-selectin antibodies
EP2194064A1 (en) 2004-05-13 2010-06-09 Eli Lilly & Company FGF-21 fusion proteins
UA93356C2 (ru) 2004-08-03 2011-02-10 Tpahctek Фарма, Инк. Белки слияния ha ochobe rage и способы их использования
JP2008509666A (ja) 2004-08-11 2008-04-03 トルビオン・ファーマシューティカルズ・インコーポレイテッド 結合ドメイン融合タンパク質
US7399746B2 (en) 2004-10-06 2008-07-15 Mcgill University Agents for wound healing
DK2325207T3 (en) 2004-11-12 2017-06-06 Xencor Inc Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US9296816B2 (en) * 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2523666T3 (es) 2005-05-31 2014-11-28 Board Of Regents, The University Of Texas System Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
CN101189334B (zh) 2005-06-03 2013-11-06 持田制药株式会社 抗cd14抗体融合蛋白质
CA2614039C (en) 2005-07-22 2015-10-13 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
CN101443357A (zh) 2005-08-12 2009-05-27 先灵公司 Mcp1融合物
KR101557375B1 (ko) * 2005-11-23 2015-10-08 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
JP2009532369A (ja) 2006-03-30 2009-09-10 リサーチ ファウンデーション オブ シティ ユニバーシティ オブ ニューヨーク 分泌性白血球プロテアーゼインヒビターによる神経再生の刺激
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2008025747A1 (en) 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
US20110020269A1 (en) 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
CN103641919B (zh) * 2007-05-30 2017-04-05 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
US8598315B2 (en) * 2007-10-02 2013-12-03 Research Foundation Of City University Of New York Protein transduction domains derived from secretory leukocyte protease inhibitor
AR064713A1 (es) 2007-12-28 2009-04-22 Consejo Nac Invest Cient Tec Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
AU2009274738B2 (en) * 2008-07-23 2012-12-13 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
US8338569B2 (en) 2008-08-04 2012-12-25 Five Prime Therapeutics, Inc. FGFR extracellular domain acidic region muteins
CN106220734A (zh) 2008-12-19 2016-12-14 宏观基因有限公司 共价双抗体及其用途
SG174862A1 (en) 2009-04-10 2011-11-28 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorder
KR101183262B1 (ko) * 2009-04-22 2012-09-14 (주)알테오젠 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법
SE533763C2 (sv) 2009-05-04 2010-12-28 Lars Hammar Upphängningsanordning
CN105557503A (zh) 2009-07-08 2016-05-11 密苏里大学管委会 利用传统大豆育种技术培育高油酸大豆的方法
AU2010319327B2 (en) 2009-11-13 2015-08-13 Five Prime Therapeutics, Inc. Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
GB201003559D0 (en) 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
WO2012003290A2 (en) 2010-06-30 2012-01-05 University Of Maryland, Baltimore Dental composites comprising nanoparticles of amorphous calcium phosphate
CA2822366A1 (en) 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
MX354359B (es) 2011-03-29 2018-02-28 Roche Glycart Ag Variantes de fragmento cristalizable (fc) de los anticuerpos.
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
KR102103476B1 (ko) * 2011-06-24 2020-04-23 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
WO2013003641A2 (en) 2011-06-28 2013-01-03 Inhibrx Llc Serpin fusion polypeptides and methods of use thereof
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
US8986688B2 (en) 2011-06-28 2015-03-24 Inhibrx, Llc WAP domain fusion polypeptides and methods of use thereof
MX358137B (es) * 2011-07-01 2018-08-06 Biogen Idec Inc Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso.
EP2802653A4 (en) 2012-01-10 2015-09-02 Univ Colorado Regents ALPHA-1 ANTITRYPSIN FUSION MOLECULE COMPOSITIONS, METHODS AND USES THEREOF
US20140051834A1 (en) 2012-06-21 2014-02-20 Hoffmann-La Roche, Inc. Incretin Receptor Ligand Polypeptide Fc-Region Fusion Polypeptides And Conjugates With Altered Fc-Effector Function
RU2015100656A (ru) 2012-06-27 2016-08-20 Ф. Хоффманн-Ля Рош Аг Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
DK2880170T3 (en) 2012-08-02 2016-10-24 Hoffmann La Roche PROCEDURE FOR PREPARING SOLUBLE FcR AS Fc FUSION WITH INERT IMMUNOGLOBULIN Fc REGION AND APPLICATIONS THEREOF
CA3138788A1 (en) 2012-12-05 2014-06-12 Sola Biosciences Llc Protein expression enhancing polypeptides
CN203917563U (zh) 2014-03-27 2014-11-05 陈广煌 一种切角模具
US20170190762A1 (en) * 2014-06-11 2017-07-06 Beth Israel Deaconess Medical Center, Inc. Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases

Also Published As

Publication number Publication date
US20210002352A1 (en) 2021-01-07
US20210024613A1 (en) 2021-01-28
EP2726092B1 (en) 2019-06-19
US20150147325A1 (en) 2015-05-28
AU2012275287A1 (en) 2014-01-16
AU2021202131A1 (en) 2021-05-06
RU2698655C2 (ru) 2019-08-28
US11965017B2 (en) 2024-04-23
UA124083C2 (uk) 2021-07-21
KR102231139B1 (ko) 2021-03-24
WO2013003641A2 (en) 2013-01-03
US8980266B2 (en) 2015-03-17
KR20140054000A (ko) 2014-05-08
RU2014102583A (ru) 2015-08-10
PL2726092T3 (pl) 2019-11-29
BR112013033799A2 (pt) 2017-02-14
US11827691B2 (en) 2023-11-28
IL230209B (en) 2020-08-31
KR20210032558A (ko) 2021-03-24
CN103917563A (zh) 2014-07-09
EP2726092A4 (en) 2015-08-19
US20130011398A1 (en) 2013-01-10
CA2839619C (en) 2021-11-16
AU2012275287B2 (en) 2017-10-05
SI2726092T1 (sl) 2019-11-29
PT2726092T (pt) 2019-10-08
EP2726092A2 (en) 2014-05-07
ME03473B (me) 2020-01-20
US10730929B2 (en) 2020-08-04
IN2013MN02441A (es) 2015-06-12
KR102084944B1 (ko) 2020-04-17
US20180179264A1 (en) 2018-06-28
US10723785B2 (en) 2020-07-28
WO2013003641A3 (en) 2013-03-21
JP6674604B2 (ja) 2020-04-01
RU2642310C2 (ru) 2018-01-24
RU2728861C1 (ru) 2020-07-31
US9920109B2 (en) 2018-03-20
RU2020124172A (ru) 2022-01-21
CY1122195T1 (el) 2020-11-25
AU2017279724A1 (en) 2018-01-25
AU2019202904A1 (en) 2019-05-16
HUE046156T2 (hu) 2020-02-28
MX2013015323A (es) 2014-06-23
NZ619023A (en) 2015-07-31
JP2018008956A (ja) 2018-01-18
US20130330769A1 (en) 2013-12-12
DK2726092T3 (da) 2019-09-30
CA3132298A1 (en) 2013-01-03
CN110066340A (zh) 2019-07-30
SG10201601621PA (en) 2016-04-28
LT2726092T (lt) 2019-10-10
KR20220003656A (ko) 2022-01-10
KR20230114318A (ko) 2023-08-01
KR20200027041A (ko) 2020-03-11
RU2017145308A3 (es) 2019-02-18
AU2017279724B2 (en) 2019-03-14
CA2839619A1 (en) 2013-01-03
AU2019202904B2 (en) 2021-01-07
AU2021202131B2 (en) 2023-01-12
US20200102371A1 (en) 2020-04-02
RU2727452C1 (ru) 2020-07-21
IL276534A (en) 2020-09-30
JP2020078325A (ja) 2020-05-28
NZ744257A (en) 2022-10-28
EP3569243A1 (en) 2019-11-20
SG10201811256QA (en) 2019-01-30
ES2746052T3 (es) 2020-03-04
JP2014523900A (ja) 2014-09-18
RU2017145308A (ru) 2019-02-18
RS59368B1 (sr) 2019-11-29
HRP20191652T1 (hr) 2019-12-13
JP2022109968A (ja) 2022-07-28
CN110551223A (zh) 2019-12-10

Similar Documents

Publication Publication Date Title
MX356517B (es) Polipéptidos de fusión de serpina y métodos de uso de los mismos.
IN2013MN02442A (es)
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
WO2013075066A3 (en) Variant serum albumin with improved half -life and other properties
EA201270775A1 (ru) Связывающие сывороточный альбумин молекулы
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
CY1117162T1 (el) Μεθοδος κατασκευης αντισωματος fc-ετεροδιμερικων μοριων χρησιμοποιωντας αποτελεσματα ηλεκτροστατικης καθοδηγησης
SG10201808523RA (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
EA201691669A1 (ru) Связывающие сывороточный альбумин домены фибронектина iii типа
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
IN2014CN00414A (es)
WO2011064758A3 (en) Fusion proteins of immunoglobulin fc and interferon- alpha
MX344219B (es) Productos farmaceuticos peptidicos mejorados para resistencia a insulina.
MX2011013455A (es) Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3.
IN2012DN03368A (es)
EA201491784A1 (ru) Антитела против лигандов рецептора в1 брадикинина
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
MX361434B (es) Proteínas de fusión npp1.
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
AU2018249796A1 (en) Antibody Fc variants for improving blood half-life
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
WO2012126118A8 (en) Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
MX2019000529A (es) Proteina de suministro cerebral.
WO2012122378A3 (en) Antibody-like proteins for therapeutic and diagnostic use

Legal Events

Date Code Title Description
FG Grant or registration